Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Factors Affecting Erythropoiesis01:24

Factors Affecting Erythropoiesis

3.2K
The cardiovascular system regulates the number of erythrocytes in the bloodstream to ensure optimal oxygen transport. It also prevents over-proliferation of these cells, which helps to maintain blood viscosity and flow rate.
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
3.2K
Erythropoiesis01:14

Erythropoiesis

4.1K
Red blood cells  (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia,...
4.1K
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

1.3K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
1.3K
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

62
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
62
Renal Corpuscle01:20

Renal Corpuscle

1.8K
The glomerulus and Bowman's capsule are two essential components of the nephron, which is the functional unit of the kidney. These microscopic structures play a critical role in the process of blood filtration to produce urine.
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
1.8K
Nephrons01:10

Nephrons

2.2K
The kidneys are intricate organs with millions of working units known as nephrons. Each nephron features two major structures: the renal corpuscle, which facilitates blood plasma filtration, and the renal tubule, which handles the glomerular filtrate. Blood supply is directly linked to the nephrons. The renal corpuscle consists of the glomerulus, a capillary network, and the Bowman's capsule, a double-walled epithelial structure that encases the glomerulus. The filtering of blood plasma...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Novel Allele, HLA-C*14:167, With a Non-Synonymous Mutation in Exon 1.

HLA·2026
Same author

COVID-19 Vaccine Reactogenicity Marks an Innate Inflammatory Response Associated With HLA Variation and Enhanced Protection.

Research square·2026
Same author

Acute High Intensity Interval Exercise Promotes Circulating Progenitor Cell Mobilization and Improves Microcirculation in Patients with Chronic Heart Failure.

Journal of cardiovascular development and disease·2026
Same author

The Complement System in the Setting of Critical Illness-A Narrative Review.

Biomolecules·2026
Same author

Neonatal Sepsis-Induced Coagulopathy in the Light of Developmental Hemostasis: Friend or Foe?

Medicina (Kaunas, Lithuania)·2026
Same author

Identification of the Novel HLA-A*02:1185N and HLA-B*41:87 Alleles, and Confirmation of HLA-A*02:1034.

HLA·2026

Related Experiment Video

Updated: Jun 14, 2025

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

20.4K

Erythropoietin Effect on Complement Activation in Chronic Kidney Disease.

Virginia Athanasiadou1, Kleio Ampelakiotou2, Eirini Grigoriou2

  • 1Department of Nephrology, School of Medicine, Aretaieion University Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.

Biomedicines
|August 29, 2024
PubMed
Summary

Erythropoietin (EPO) therapy in chronic kidney disease patients activates the complement system. This activation, coupled with reduced complement regulatory proteins, may drive inflammation and kidney injury.

Keywords:
chronic kidney diseasecomplementerythropoietinlymphocytes

More Related Videos

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

525
Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.2K

Related Experiment Videos

Last Updated: Jun 14, 2025

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

20.4K
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

525
Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.2K

Area of Science:

  • Immunology
  • Nephrology
  • Biochemistry

Background:

  • The complement system is crucial for innate immunity but can cause tissue damage when dysregulated.
  • Kidney disease (CKD) is frequently associated with complement system abnormalities.
  • Erythropoietin (EPO) is used to treat anemia in CKD patients.

Purpose of the Study:

  • To investigate the impact of EPO administration on the complement system in CKD patients.
  • To assess changes in complement factors and regulatory proteins during EPO therapy.

Main Methods:

  • Studied 20 CKD patients undergoing EPO therapy.
  • Measured serum levels of complement factors C3a and C5a.
  • Assessed expression of complement regulatory proteins (CregPs) CD55, CD46, and CD59 on immune cells.

Main Results:

  • EPO therapy led to increased serum C3a and C5a levels.
  • Statistically significant increase in C3a (p < 0.05).
  • Significant decrease in CD55 on CD4+ T and B cells (p < 0.05) and CD59 on CD4+ and CD8+ T cells (p < 0.05) compared to controls.

Conclusions:

  • EPO therapy induces complement activation in CKD patients.
  • Simultaneous downregulation of CRegPs (CD55, CD59) may permit uncontrolled complement activation.
  • This process could contribute to kidney tissue injury and disease progression in CKD.